Predicting Breakdown of the Blood-Brain Barrier in Multiple Sclerosis without Contrast Agents

References

1. 1.↵
   1. Raine CS,
   2. McFarland HF,
   3. Tourtellotte WW

   . Multiple Sclerosis: Clinical and Pathogenic Basis. London, UK: Chapman and Hall; 1997
2. 2.↵
   1. Barnett MH,
   2. Prineas JW

   . Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458–68

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Polman CH,
   2. Reingold SC,
   3. Banwell B,
   4. et al

   . Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302

   CrossRefPubMedWeb of Science
4. 4.↵
   Physician Fee Schedule. Centers for Medicare and Medicaid Services. http://www.cms.gov/apps/physician-fee-schedule/license-agreement.aspx. Accessed September 13, 2011
5. 5.↵
   1. Kay J

   . Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 2008; 67(supple 3): iii66–69

   Abstract/FREE Full Text
6. 6.↵
   1. Perazella MA

   . Current status of gadolinium toxicity in patients with kidney disease. Clin J Am Soc Nephrol 2009; 4: 461–69

   Abstract/FREE Full Text
7. 7.↵
   1. Moren-Romero JA,
   2. Sequira S,
   3. Mascaro JMJ,
   4. et al

   . Nephrogenic systemic fibrosis: a case series suggesting gadolinium as a possible aetiological factor. Br J Dermatol 2007; 157: 783–87

   CrossRefPubMedWeb of Science
8. 8.↵
   1. Dillman JR,
   2. Ellis JH,
   3. Cohan RH,
   4. et al

   . Frequency and severity of acute allergic-like reactions to gadolinium-containing i.v. contrast media in children and adults. AJR Am J Roentgenol 2007; 189: 1533–38

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Hunt CH,
   2. Hartman RP,
   3. Hesley GK

   . Frequency and severity of adverse effects of iodinated and gadolinium contrast materials: retrospective review of 456,930 doses. AJR Am J Roentgenol 2009; 193: 1124–27

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Kataoka H,
    2. Taoka T,
    3. Ueno S

    . Early contrast-enhanced magnetic resonance imaging with fluid-attenuated inversion recovery in multiple sclerosis. J Neuroimaging 2009; 19: 246–49

    CrossRefPubMed
11. 11.↵
    1. Bagnato F

    . Uncovering and characterizing multiple sclerosis lesions: the aid of fluid-attenuated inversion recovery images in the presence of gadolinium contrast agent. J Neuroimaging 2009; 19: 201–04

    CrossRefPubMed
12. 12.↵
    1. Sled JG,
    2. Zijdenbox AP,
    3. Evans AC

    . A nonparametric method for automatic correction of intensity nonuniformity in MRI data. IEEE Trans Med Imaging 1998; 17: 87–97

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Carass A,
    2. Wheeler MB,
    3. Cuzzocreo J,
    4. et al

    . A joint registration and segmentation approach to skull stripping. In: Proceedings of the IEEE International Symposium on Biomedical Imaging: From Nano to Macro, Chicago, Illinois; March 30–April 2, 2011: 656–59
14. 14.↵
    1. Moraal B,
    2. Wattjes MP,
    3. Geurts JJ,
    4. et al

    . Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology 2010; 255: 154–63

    CrossRefPubMedWeb of Science
15. 15.↵
    1. Di CZ,
    2. Crainiceanu CM,
    3. Caffo BS,
    4. et al

    . Multilevel functional principal component analysis. Ann Appl Stat 2009; 3: 458–88

    PubMed